Crystal Pharmatech Launched China's First Training Course on Polymorphism
Crystal Pharmatech Co.,Ltd researchers held an incredibly successful two-day training program on polymorphism and solid state characterization held at Suzhou Industrial Park, China March 24th and 25th.
- (1888PressRelease) April 01, 2011 - The training program was attended by over 130 researchers representing more than 70 China based pharmaceutical companies. Attendees included senior scientists and managers from global Pharm R&D centers in China including GSK, Novartis, Roche as well as other leading China-based companies including Huahai, Hengrui, and Donyangguang.
Polymorphism in drug development can significantly impact: bioavailability; API and formulation processing; as well as drug product performance in a multitude of areas. Therefore, a thorough understanding of solid phases of a drug substance is crucial in the whole drug discovery and development life cycle.
Sessions focused on illuminating the participants on the impact of polymorphism and solid state properties in pharmaceutical development. Real "case studies", characterization tools, and problem solving skills were discussed in-depth.
Topics included:
• Polymorphism and its impact in API and formulation development
• Hydrates
• Amorphous solid dispersions
• Pharmaceutical Cocrystals
• Polymorph IP development and protection
• Solid state characterization tools
• Application of solid state NMR to the pharmaceutical industry
• Chiral resolution through crystallization
Researchers came out of the session with a new outlook on how understanding polymorphism and solid state properties in drug substance and drug product can significantly enhance the quality of their processes and product. "It was incredible to see the powerful solid state characterization concepts and tools available to us that can drive robustness and productivity in our processes" explains Dr. Yen from Tai-Gen Biotechnology, a top innovator pharmaceutical company in Taiwan. "A basic understanding of solid state properties and polymorphism is critical to API development and will definitely enhance the overall quality of our business."
A post meeting survey indicated that 97% of the attendees would either attend another Crystal Pharmatech training or recommend it to their colleagues. Additionally, 93% of the attendees mentioned that they were very satisfied with the training program.
"The overwhelmingly positive response to the training was well beyond our highest expectations" explains Alex M. Chen, CEO of Crystal Pharmatech Co., Ltd. "The issues facing China based researchers are exactly the same as what we have dealt with and solved for years in US based pharma companies. By implementing straightforward characterization tools and routine solid state problem solving, many of the participants' problems can be solved in a short period of time. These are incredibly exciting times in China and I am honored to be a part of the pharma learning curve while driving the innovation."
One of the missions of Crystal Pharmatech Co., Ltd is to aid China based pharma companies in "catching up" with western pharma companies in discovery and development of innovative drugs. We believe that our training and experience will be critical to this mission and will continue to hold these training sessions while response remains positive.
Crystal Pharmatech Co., Ltd is the first technology-driven solid state research CRO based in China. Crystal Pharmatech researchers have combined greater than 40 years experience in top-tier pharmaceutical companies focusing on solid state API and drug product development issues. Whether you are a top-tier innovator company or a pre-emerging biotech, Crystal Pharmatech can handle all of your solid-state property needs. It offers a full range of services from being the solid state characterization arm of your company to consultation or training on a specific issue.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam